Physician profile

Nikesha A Duplan

Adult Health (Nurse Practitioner) · Brooklyn, NY

NPI 1700336484

$1,359.10

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,278.45

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Viiv Healthcare Company $701.31 2022-2024 Dovato, Apretude, Cabenuva
Gilead Sciences, INC. $304.56 2024 Descovy
Abbvie INC. $215.73 2023-2024
Teva Pharmaceuticals USA, INC. $43.35 2024 Austedo Xr, Uzedy
Pfizer INC. $29.49 2023
Janssen Pharmaceuticals, INC $28.48 2021
Lundbeck LLC $20.58 2024 Abilify Maintena
Merck Sharp & Dohme LLC $15.60 2023 Vaxneuvance, Pneumovax 23, Vaxelis

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nikesha A Duplan

$1,359.10

in general payments reported 2019-2025

Years
2021-2024
Top company
Viiv Healthcare Company

https://glasscript.com/doctor/10605708/nikesha-a-duplan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.